Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729134 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL158736 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL208566 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL5982864 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL4941637 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL11203648 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL4809983 | 1.00 | TSHR (0.45) | TSHRRECQLGLAHPGDMAPK1 | |
| Potassium Ion SCHEMBL8777175 | 0.97 | NAAA (0.42) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL2120646 | 0.92 | FABP3 (0.47) | EPHX2 | |
| SCHEMBL11128465 | 0.91 | RECQL (0.45) | TSHRRECQLGLAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014128564-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-08-28 | — | — | WO | claimed |
| EP-1938800-A1 | Sirolimus nanodispersion | Ranbaxy Laboratories Limited (IN) | 2008-07-02 | — | — | EP | claimed |
| US-20080138405-A1 | SIROLIMUS NANODISPERSION | RANBAXY LABORATORIES LIMITED (IN) | 2008-06-12 | — | — | US | claimed |
| EP-1556001-A2 | THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO AND THROUGH COVERING EPITHELIA | UMD, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1545473-A2 | MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-29 | — | — | EP | claimed |
| US-20040151774-A1 | Therapeutic compositions for drug delivery to and through covering epithelia | UMD, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004056336-A2 | CONTROLLED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-08 | — | — | WO | claimed |
| WO-2004041118-A2 | THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO AND THROUGH COVERING EPITHELIA | UMD, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2003103637-A2 | MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS | RANBAXY LABORATORIES LIMITED (IN) | 2003-12-18 | — | — | WO | claimed |
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | AZURITY PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3824296-B1 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING TESTOSTERONE TRIDECANOATE AND/OR TESTOSTERONE DODECANOATE FOR TREATING LIVER DISEASES | LIPOCINE INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250352482-A1 | AMORPHOUS DOSAGE FORM CONTAINING EBSELEN | SOUND PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250332165-A1 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250302819-A1 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2001001960-A1 | CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0436240-B2 | Process for preparing a high bulk density detergent composition having improved dispensing properties | UNILEVER NV (NL) | 2000-06-14 | — | — | EP | disclosed |
| US-4820448-A | DETERGENTS, GOOD FLOW, POURABLE, PUMPABLE AT ROOM TEMPERATURE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-04-11 | — | — | US | disclosed |
| US-4649169-A | Crosslinked vinyl polymer compositions and process for preparing molded shaped articles | HENKEL CORPORATION (US) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | CSNK1D, PPARD, TP53 | TSHR 2930/4885RECQL 2062/4885GLA 1087/4885 |
| US-20250302819-A1 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | ABL1, KRAS, PIK3CA | TSHR 3596/4885RECQL 2803/4885GLA 3390/4885 |
| US-20250352482-A1 | AMORPHOUS DOSAGE FORM CONTAINING EBSELEN | SBDS, RPS27L, CYP2C9 | TSHR 3659/4885RECQL 1310/4885GLA 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.